Insights

Cosmetic giant, Estée Lauder has launched legal proceedings in the High Court against perfumer Jo Malone, her fragrance company Jo Loves, and high street retailer, Zara, for trade mark infringement, passing off, and breach of contract.

Chartered Trade Mark Attorney, Alexandra Nott explores some of the reasons that trade mark protection remains crucial in today’s business environment.

In this insight, Biotechnology partner Kit Wilkins reviews the US Supreme Court’s decision to Consider “Skinny Labels” in Generic Drug Patent Dispute. The decision could result in significant implications of generic medicines in the US.

In this insight, Holly Rocliffe from Dehns Biotechnology group explores the recently handed down decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161^[1], in which the Full Court of the Federal Court of Australia (Full Court) has ruled that patent term extension (PTE) is only available for patents which claim an active pharmaceutical ingredient (API).

The first decision from the UPC on sufficiency — handed down in the Amgen v. Sanofi case — provides the first clear guidance on how the court will address whether a patent’s disclosure is sufficient.

In this insight, Dehns Partner Rob Jackson and Conor Wilman from our Technology, Software and Engineering group explore the UPC’s Court of Appeal recent issues of two important decisions about how it will assess inventive step in patent cases.

The UK Intellectual Property Office (UKIPO) is consulting on possible changes to the UK design framework with the aims of improving design validity, simplifying the regime, and protecting emerging forms of design.

The G1/23 ruling from the European Patent Office marked a pivotal shift in how marketed products are treated as prior art, redefining the principles of reproducibility and disclosure across Europe. Dehns has collaborated with international patent experts to provide a global perspective on the ruling.